Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2019 07:01 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences Reports Further Positive EDP1815 Interim Clinical Data in Patients with Psoriasis at High Dose in Phase 1b Trial

--EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo-- --Reduction in Mean Lesion Severity Score (LSS) at 28 Days Consistent with Low Dose Cohort-- -- Dose Response Trends...
November 05, 2019 07:00 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences Announces Further Positive Interim Phase 1b Clinical Data in Psoriasis and Reports Third Quarter 2019 Financial Results

--EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo----Reduction in Mean Lesion Severity Score (LSS) at 28 Days Consistent between High and Low Dose Cohort---- Dose Response...
October 29, 2019 08:00 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Tuesday, November 5th

CAMBRIDGE, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences (NASDAQ:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting...
September 26, 2019 16:05 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences to Present at the 2019 Cantor Global Healthcare Conference

CAMBRIDGE, Mass,, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, today...
September 20, 2019 07:00 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences to Host Key Opinion Leader Symposium on Unmet Need in Mild to Moderate Psoriasis and Potential for EDP1815

CAMBRIDGE, Mass., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, today...
September 17, 2019 07:00 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences Announces the Appointment of David Epstein as Chairman of its Board of Directors

CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics,...
September 03, 2019 08:00 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic...
August 06, 2019 07:01 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences Reports Positive EDP1815 Interim Clinical Data in Psoriasis Patients at Low Dose in Ongoing Phase 1b Trial

-EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo--Patients Dosed with EDP1815 Showed a Reduction in Mean Lesion Severity Score vs. Placebo--Reductions Observed in Cellular...
August 06, 2019 07:00 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences Announces Positive Interim Phase 1b Clinical Data and Provides Second Quarter 2019 Financial Results

-EDP1815 and EDP1066 were Well Tolerated with No Overall Difference Reported from Placebo--Clinical Response Observed Consistent with Reductions in Cellular Histological and Blood Immune Cell...
July 30, 2019 08:00 ET | Source: Evelo Biosciences, Inc.

Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Tuesday, August 6th

CAMBRIDGE, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a biotechnology company developing oral biologics that act on cells in the small intestine with...